GENOVIS: THE NEW SHARE ISSUE WAS OVERSUBSCRIBED BY 102%

On closing day, September 30, the new share issuing with preferential rights to existing shareholders in Genovis was oversubscribed by 102 %.

14.2 million shares was subscribed for in the new share issue that closed on September 30. In the new share issuing of 7,033,233 shares, 61 % was subscribed with preferential rights. Allotment of shares subscribed without subscription rights shall first hand go to those who subscribed with preferential rights proportional to their subscription for shares with preferential rights, and at second hand to those who subscribed without preferential rights proportional to their subscription. The issuing ensures Genovis approximately 7 MSEK before issue expenses. The number of shares increased from 14,066,466 to 21,099,699 and the share capital increased from 5,626,586.40 to 8,439,879.60. Contract note and notification of allotment of shares subscribed without subscription rights is estimated to be sent out Tuesday October 6, 2009. As of October 1 Thenberg & Kinde Fondkommission is our certified advisor

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links